Trials / Completed
CompletedNCT00220194
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (planned)
- Sponsor
- San Bernardino Urological Associates Medical Group Inc · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | leuprolide acetate |
Timeline
- Start date
- 2003-04-01
- Completion
- 2005-06-01
- First posted
- 2005-09-22
- Last updated
- 2016-10-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00220194. Inclusion in this directory is not an endorsement.